Literature DB >> 25577553

Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma.

Kicheol Kil1, Jae-Eun Chung1, Ho Jeong Pak1, In-Cheul Jeung1, Jang Heub Kim1, Hyun Hee Jo1, Mee-Ran Kim2.   

Abstract

OBJECTIVES: To evaluate the usefulness of CA125 levels in the differential diagnosis of adenomyosis and myoma. This has been addressed by few, if any, previous studies. STUDY
DESIGN: Preoperative serum CA125 levels were measured in 2149 women who were diagnosed at total hysterectomy as having adenomyosis, myoma, endometriosis, and/or normal pelvis. Their medical records were retrieved and reviewed.
RESULTS: The mean serum CA125 level in the adenomyosis patients was significantly greater than that in the patients diagnosed with myoma (65.21±96.60 U/mL vs.12.86±14.23 U/mL, respectively; P<0.001). In the differential diagnosis of adenomyosis and myoma, the cut-off serum CA125 level with the highest accuracy (78.8%) and highest diagnostic value (61.2%) was 19 U/mL. Using this cut-off value, the negative predictive value was 69.5%, and the positive predictive value was 76.5%. These results are clearly superior to those of the empirical single cut-off value of 35 U/mL. Receiver operating characteristic curve analysis revealed the area under the curve for differentiating adenomyosis from myoma was 0.776, indicating good diagnostic performance.
CONCLUSION: In the differential diagnosis of adenomyosis and myoma, cut-off values for CA125, particularly the cut-off value of 19 U/mL, provide improved diagnostic performance. Serum CA125 testing can be performed during the initial screening of women with possible adenomyosis to differentiate this condition from myoma, although the diagnostic accuracy of using CA125 testing alone is limited.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adenomyosis; CA125; Myoma

Mesh:

Substances:

Year:  2014        PMID: 25577553     DOI: 10.1016/j.ejogrb.2014.12.008

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  12 in total

1.  Female genital tuberculosis presented with primary infertility and persistent CA-125 elevation: A case report.

Authors:  Qian Feng; Xiaoxia Hu; Jing Zhao; Jingyao Huang; Liling Liu
Journal:  Ann Med Surg (Lond)       Date:  2022-05-03

2.  Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis.

Authors:  Amanda M Ecker; Dina Chamsy; R Marshall Austin; Richard S Guido; Ted T M Lee; Suketu M Mansuria; Noah B Rindos; Nicole M Donnellan
Journal:  J Gynecol Surg       Date:  2018-08-01

3.  Predisposing factors for predicting the therapeutic response of adenomyosis after uterine artery embolization: serum CA125 levels and accompanying endometriosis.

Authors:  Rui Zheng; Dan Zeng; Ting-Ting Wan; Wen-Bo Guo; Yan Guo; Ming-Juan Liu
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

4.  CA125 modified by PLT and NLR improves the predictive accuracy of adenomyosis-derived pelvic dense adhesion.

Authors:  Caixia Jiang; Chao Liu; Jing Guo; Li Chen; Ning Luo; Xiaoyan Qu; Weihong Yang; Qing Ren; Zhongping Cheng
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

5.  Recurrence-associated factors of laparoscopic adenomyomectomy for severely symptomatic adenomyoma.

Authors:  Wentao Yu; Guanyuan Liu; Chongdong Liu; Zhenyu Zhang
Journal:  Oncol Lett       Date:  2018-07-05       Impact factor: 2.967

6.  Characteristics of Peripheral Immune Function in Reproductive Females with Uterine Leiomyoma.

Authors:  Zhi-Qin Liu; Mei-Yin Lu; Ru-Liang Sun; Zhi-Nan Yin; Bin Liu; Yang-Zhe Wu
Journal:  J Oncol       Date:  2019-10-24       Impact factor: 4.375

7.  Abdominopelvic leiomyoma with large ascites: A case report and review of the literature.

Authors:  Yi-Wei Wang; Qiong Fan; Zhao-Xia Qian; Jin-Jin Wang; Yu-Hong Li; Yu-Dong Wang
Journal:  World J Clin Cases       Date:  2021-02-26       Impact factor: 1.337

8.  Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence.

Authors:  Aloma L D'Souza; John R Chevillet; Pejman Ghanouni; Xinrui Yan; Muneesh Tewari; Sanjiv S Gambhir
Journal:  PLoS One       Date:  2018-03-16       Impact factor: 3.240

9.  Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study.

Authors:  Qing Li; Yan Ding; Xu-Yin Zhang; Wei-Wei Feng; Ke-Qin Hua
Journal:  J Int Med Res       Date:  2018-03-19       Impact factor: 1.671

10.  Evaluation of adenomyosis after gonadotrophin-releasing hormone agonist therapy using ultrasound post-processing imaging: a pilot study.

Authors:  Szu-Yuan Chou; Cindy Chan; Yu-Chieh Lee; Tzu-Ning Yu; Chii-Ruey Tzeng; Chi-Huang Chen
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.